A small crossover trial found almond milk offered no postprandial glycaemic benefit over 2% cow milk in adults with type 2 diabetes, with the primary glucose endpoint null. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
A single-centre randomised controlled trial testing multidisciplinary multifactorial care against standard care in 192 adults with type 2 diabetes, with a modest HbA1c reduction and improved eGFR. PICO summary and expert commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
A four-arm community trial finds integrated diabetes-and-periodontitis self-management improves glycaemic control and oral health more than single-disease care. PICO summary and commentary.
A controlled study finds adding vildagliptin to premixed insulin reduces glycaemic variability and improves time in range in type 2 diabetes. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.